GDF8/TGF-beta inhibitors (Rigel Pharmaceuticals)

N/A

Report date: 2025/03/20 15:49:04
NME

Base Information

Drug NameGDF8/TGF-beta inhibitors (Rigel Pharmaceuticals)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGrowth/differentiation factor 8 inhibitorsActivin receptor-like kinase 1 inhibitors
TargetsActivin receptor-like kinase 1Growth/differentiation factor 8
Therapy Area/IndicationsMusculoskeletal development disorder
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRigel Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesRigel Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsMusculoskeletal development disorder
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A